# BrUOG360 (NCT04253262)

> A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: copanlisib plus rucaparib
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04253262
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Brown University
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Rucaparib; Copanlisib
- Enrollment: 13
- Primary outcome: Maximum Tolerated Dose
- Primary outcome: Response

## Indexed commentary on BrUOG360 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bruog360-nct04253262